CDK7/12-IN-1

• CAT Number: I043821
• CAS Number: 2654075-94-0
• Molecular Formula: C25H34N8O
• Molecular Weight: 462.59
• Purity: ≥95%
• Synonyms: (3R,4R)-4-[[[7-[(2,7-dimethylimidazo[1,2-a]pyridin-3-yl)methylamino]-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol
• InChI: InChI=1S/C25H34N8O/c1-15(2)19-12-29-33-23(28-13-20-17(4)30-24-9-16(3)6-8-32(20)24)10-22(31-25(19)33)27-11-18-5-7-26-14-21(18)34/h6,8-10,12,15,18,21,26,28,34H,5,7,11,13-14H2,1-4H3,(H,27,31)/t18-,21+/m1/s1
• InChIKey: IHXKZRXUGKSPTO-NQIIRXRSSA-N
• SMILES: CC1=CC2=NC(=C(N2C=C1)CNC3=CC(=NC4=C(C=NN34)C(C)C)NC[C@H]5CCNC[C@@H]5O)C

CDK7/12-IN-1（Cat No.:I043821）is a selective inhibitor targeting cyclin-dependent kinases 7 and 12 (CDK7 and CDK12), enzymes that regulate transcription and RNA processing. CDK7 is involved in the phosphorylation of RNA polymerase II, essential for transcription initiation, while CDK12 is implicated in the regulation of RNA splicing and DNA damage response. By inhibiting these kinases, CDK7/12-IN-1 can disrupt the transcriptional machinery, leading to reduced cancer cell proliferation and increased sensitivity to DNA damage. It holds potential as a therapeutic strategy for treating cancers, especially those driven by dysregulated transcriptional activity.